FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythemia), in adults with anemia.
Imatinib—the pathbreaking cancer drug that gave Philadelphia chromosome-positive chronic myeloid leukemia patients near-normal life expectancies—now stands poised to save even more lives.Â
